Eliem Therapeutics, Inc. Stock News

Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.

Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. Eliem Therapeutics came to this decision after co

Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal excitability disorders, said it is exploring its str

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuro

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Shares of Eliem Therapeutics fell more than 50% Monday after reporting disappointing clinical data.

Eliem Therapeutics Inc's (NASDAQ: ELYM) ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) failed to achieve statistically significant separation from placebo on the trial's prim

SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neur

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 3:00 PM ET.

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuro

Eliem Therapeutics Inc (ELYM) shares closed today 11.2% lower than it did at the end of yesterday. The stock is currently up 5.6% year-to-date, down 30.5% over the past 12 months, and down 30.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $13.74 and as low as $8.65 this week.Shares closed 62.8% below its 52-week high and 35.4% above its 52-week low.Trading volume this week was 52.9% higher than the 10-day average and 77.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -2264.4% The company's stock price performance over the past 12 months lags the peer average by 311.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Eliem Therapeutics Inc (ELYM) shares closed today 11.2% lower than it did at the end of yesterday. The stock is currently up 5.6% year-to-date, down 30.5% over the past 12 months, and down 30.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $13.74 and as low as $8.65 this week.Shares closed 62.8% below its 52-week high and 35.4% above its 52-week low.Trading volume this week was 67.4% higher than the 10-day average and 83.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -2264.4% The company's stock price performance over the past 12 months lags the peer average by 248.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Eliem Therapeutics Inc (ELYM) shares closed today 38.3% higher than it did at the end of yesterday. The stock is currently down 9.1% year-to-date, down 40.2% over the past 12 months, and down 40.2% over the past five years. Today, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $12.26 and as low as $9.29 this week.Shares closed 55.7% below its 52-week high and 61.2% above its 52-week low.Trading volume this week was 57.6% lower than the 10-day average and 65.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -757.3% The company's stock price performance over the past 12 months lags the peer average by 567.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.